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ABSTRACT
Objective: The objective of this study was to evaluate the prophylactic effect of Kadukkai maathirai (KM) against ethanol-induced hepatotoxicity in rats.
Methods: Four groups (n=6) of adult female Sprague–Dawley rats were used. Ethanol was administered in the dose of 45% v/v 15 mL/kg/body 
weight twice a day for 8 weeks in the study. The four groups were treated orally for 8 weeks with 2% gum acacia (control), ethanol (toxic control), 
ethanol + KM 72 mg/kg, and ethanol + KM 400 mg/kg, respectively. At the end of 8 weeks, blood was collected by a retro-orbital puncture for the 
estimation of liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]). The liver was dissected out for histopathology. 
Using one-way ANOVA and post hoc Tukey’s test, the data were analyzed.
Results: There was a significant (p<0.05) decrease in the serum AST and ALT level in rats treated with KM 72 mg/kg as compared to toxic control. 
Liver parenchyma showed near normal architecture in KM 72 mg/kg-treated group as compared to ethanol-treated group which showed extensive 
ballooning degeneration of hepatocytes and microvesicular steatosis.
Conclusion: KM, in the dose of 72 mg/kg, which is the therapeutic dosage described in Siddha additional literature, exerted hepatoprotective effect 
against ethanol-induced liver damage in rats.
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INTRODUCTION
Chronic liver disease remains a major health problem globally, 
affecting more than 10% of the population [1]. Worldwide, viral 
hepatitis, alcohol, and non-alcoholic fatty liver disease are the 
common causative factors of liver dysfunction [2-4]. They are also 
considered to be risk factors for hepatocellular carcinoma (HCC) [5]. 
The common cause of death in these patients is cardiovascular 
events, but they also have an increased liver-related mortality rate 
predominantly when cirrhosis and HCC develop [6,7]. Alcoholic 
liver disease (ALD) ranges from steatosis to frank cirrhosis. More 
than one stage of the disease might be present simultaneously in 
a patient with ALD [8,9]. A person with chronic ethanol intake will 
end up with liver damage by a process which involves cytokines, 
oxidative and nitrosative stress, hypoxia, and alterations in energy 
metabolism [10-12]. Asceticism is an important treatment measure 
for patients with ALD but difficult to sustain. Agents such as 
naltrexone and acamprosate have been used to maintain asceticism, 
but they did not show any major impact on alcoholics who were not 
detoxified or became ascetic [13,14].
Steroids and anticytokines have been used but are associated with 
adverse effects [15]. Treatment of most of the liver disorders including 
ALD largely involves removal of toxins, use of phytochemical agents, 
and other supportive agents for the regeneration of the liver. Drugs 
obtained from plants, namely silymarin, phyllanthin, lecithin, catechin, 
glycyrrhizin, picroside, baicalein, anddaphnoretin, are used for the 
regeneration of the liver [16].
There are various studies which have demonstrated excellent 
hepatoprotective effects of different herbs used in traditional Indian 
medicine [17,18]. Siddha is one of the earliest systems of medicine 
practiced in India, Sri Lanka, and Malaysia [19]. Kadukkai maathirai 
(KM) is a polyherbal Siddha preparation described in the traditional 
Siddha literature wherein it is indicated for anemia, sobai (generalized 
edema due to liver disease), and mahodharam (ascites due to liver 
disease) by Siddha doctors [20,21].
KM is composed of Terminalia chebula, Piper nigrum, Eclipta alba, Citrus 
limon, and ferrous sulfate (processed by traditional method) [21]. 
Each plant in this formulation has individually demonstrated the 
hepatoprotective effect in rats in the previous studies. T. chebula (fruit) 
has been shown to prevent isoniazid, rifampicin, and pyrazinamide-
induced liver toxicity [22]. P. nigrum has shown a hepatoprotective 
effect in carbon tetrachloride as well as thioacetamide-induced 
liver damage in rats [23,24]. Ethanolic extract of C. limon produced 
a reduction in the elevated liver enzymes in carbon tetrachloride 
(CCl4)-induced liver toxicity in rats [25]. E. alba produced a significant 
restoration of microsomal enzymes, aminopyrine N-demethylase, 
glucose 6-phosphatase, ALP, and lysosomal acid phosphatase in CCl4-
induced hepatotoxicity in rats [26,27]. Studies with KM have shown its 
hepatoprotective effect in CCl4-induced hepatic damage in rats [21].
The current experiment was undertaken to investigate the 
hepatoprotective outcome of KM treatment in rats with alcohol-
induced toxicity.
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MATERIALS AND METHODS
Drug
KM was procured from SKM Siddha and Ayurveda Ltd., Erode, Tamil 
Nadu, India.
Animals
Hepatoprotective effects of KM were evaluated using adult female Sprague–
Dawley rats (weighing 150–200 g). Female Wistar rats (weighing 150–
200 g) were used for acute toxicity study. They were kept individually in 
polypropylene cages and maintained at a temperature of 27±3°C, relative 
humidity of 60±10%, and 12 h light/dark cycle. The experiments were 
conducted according to the ethical norms laid down by the Committee for 
the Purpose of Control and Supervision on Experimentations on Animals 
guidelines after approval of the experimental protocol by the Institutional 
Animal Ethics Committee, Manipal.
Acute toxicity study
The OECD 423 guideline (acute toxic class method) was followed 
for the experiment. KM was dissolved in normal saline and was 
administered through oral gavage to female Wistar rats (n=3) in a 
dose of 5 mg/kg body weight. The rats were observed for first 24 h 
for any signs and symptoms of toxicity or death and later for 2 weeks. 
As no toxic symptoms were observed in all three animals, the dose of 
KM was escalated to 50 mg/kg body weight in additional three rats. 
The procedure was repeated with higher doses of KM - 300 mg/kg, 
2000 mg/kg, and 4000 mg/kg body weight using three rats for each 
dose. There were no toxic symptoms observed even at the highest dose.
Hepatoprotective activity
Two doses of KM were selected for evaluation of its hepatoprotective 
effect. One of the doses selected was based on the human dose of KM. As 
the human dose of KM is 200 mg twice a day, the human equivalent dose 
for rat, i.e., 36 mg/kg body weight was derived based on body surface 
area. The other dose selected was 400 mg/kg body weight which is one-
tenth of the maximum tolerated dose (4000 mg/kg body weight based 
on acute toxicity study).
Four groups with six rats in each (a total of 24 rats) were used. All groups 
received respective drugs for 8 weeks. Group 1 (control) received 2% 
gum acacia 1 mL/kg orally. Hepatotoxicity was induced in other rats 
(Groups 2–4) by administering ethanol orally 45% v/v 15 mL/kg body 
weight twice a day for 8 weeks. Group 2 (toxic control) received ethanol. 
Groups 3 and 4 were treated with KM - 72 mg/kg and 400 mg/kg, 
respectively, along with ethanol for 8 weeks. After 8 weeks of treatment, 
blood was collected by retro-orbital puncture. Biochemical estimation 
of liver enzymes such as aspartate transaminase (AST) and alanine 
transaminase (ALT) was done using standard biochemical kits [28].
Rat liver was collected and fixed in 10% formaldehyde solution for 
microscopic examination using hematoxylin-eosin stain.
Statistics
Statistical program SPSS 16.0 was used. Data were expressed in terms 
of mean and standard deviation. One-way ANOVA followed by post hoc 
Tukey’s test was used. A p<0.05 was considered statistically significant.
RESULTS
Biochemical estimation in serum
Chronic administration of ethanol showed a significant (p<0.05) rise in 
serum AST and ALT levels as compared to normal control. Treatment 
with KM at 72 mg/kg significantly (p<0.05) prevented the ethanol-
induced rise in AST and ALT levels when compared to the rats who were 
administered ethanol only (Table 1). Higher dose (400 mg/kg) of KM 
did not have any beneficial effect in ethanol-induced hepatotoxicity.
Histopathology
Chronic oral administration of ethanol to rats caused enlargement of the 
liver. Histopathology of liver of normal rats showed liver parenchyma 
with normal architecture (Fig. 1a). There was extensive ballooning 
degeneration of hepatocytes and microvesicular steatosis in ethanol 
only treated group (Fig. 1b). Section of liver parenchyma of rats treated 
with KM 72 mg/kg along with ethanol showed near normal architecture 
(Fig. 1c). Focal areas of apoptosis and giant mitochondria in hepatocytes 
were evident in rats treated with 400 mg/kg of KM (Fig. 1d).
DISCUSSION
In the present study, the effect of KM on ethanol-induced liver injury was 
evaluated. Alcohol is a major cause of hepatic dysfunction characterized by 
fatty liver, hepatitis, and cirrhosis [29]. It produces a dose-related damage 
in the liver [30]. Reactive oxygen species play an important role in the 
ethanol-induced hepatic damage. They damage hepatocyte membrane, 
DNA, mitochondria, and other cellular components. In addition, cytokines 
released from activated Kupffer cells cause necrosis of hepatocytes followed 
by fibrosis [31-35]. In this study, treatment with ethanol caused an elevation 
of hepatic enzymes such as ALT and AST which indicates hepatocyte 
membrane disruption and mitochondrial damage, respectively [36].
KM, in a lower dose, prevented ethanol-induced hepatotoxicity as 
was evident from the biochemical and histopathological changes. 
KM consists of herbs such as T. chebula, P. nigrum, E. alba, and C. 
limon [21]. C. limon has antioxidants such as Vitamin C and flavonoids 
which target the free radicals [37]. P. nigrum exerts antioxidant effect 
which could be mediated by flavonoids and phenolic constituents. 
It has been shown to inhibit lipid peroxidation and generation of 
superoxide free radicals [38,39]. Gallic acid and chebulic acid are 
important constituents of T. chebula. Gallic acid has antioxidant 
and anti-inflammatory properties. Chebulic acid is known to be an 
antioxidant and hepatoprotective agent. It has produced immune-
modulation effects on IL-6 and IL-10 in collagen-induced arthritis 
model [40-44]. Coumestans, present in E. alba, have been shown 
to exert a protective effect in liver disorders and stimulate liver cell 
regeneration [45]. In an earlier study, a 28-day treatment with KM (36 
Table 1: Effect of K. maathirai on liver enzyme levels in 
ethanol‑induced liver damage in prague–dawley rats
Group AST, IU/L ALT, IU/L
Group 1, vehicle control 49±6.9 25±2.9
Group 2, ethanol control 126±7.3* 57±2.4*
Group 3, ethanol+KM 72 mg/kg 64±5.9** 32±3.7**
Group 4, ethanol+KM 400 mg/kg 113±16.2 52±13.6
Values are expressed in mean±SD, KM: Kadukkai maathirai, *p<0.05 vs. control 
group, ** p<0.05 versus ethanol group, SD: Standard deviation
Fig. 1: Histopathology of the liver. (a) Normal rats (b) ethanol‑
treated group (c) ethanol + Kadukkai maathirai 72 mg/kg‑treated 
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and 72 mg/kg) showed a protective effect against carbon tetrachloride-
induced hepatotoxicity in rats [19].
Therefore, we hypothesize that the hepatoprotective activity shown by a 
low dose of KM could be due to the presence of active phytoconstituents 
in it. As KM is a herbomineral formulation, further analysis needs to be 
done to find the reason for the variation in response at different doses.
CONCLUSION
Overall, the result of the present study indicates that KM demonstrated 
a significant hepatoprotective activity against ethanol-induced 
hepatotoxicity in rats.
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